• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

World Conference on Lung Cancer (WCLC) 2024

September 07 - 10, 2024

  1. Durvalumab
  2. Volrustomig
  3. Rilvegostomig
  4. Trastuzumab Deruxtecan
  5. Osimertinib
  6. Durvalumab Tremelimumab
  7. Durvalumab Monalizumab Oleclumab Datopotamab Deruxtecan Volrustomig
  8. Datopotamab Deruxtecan
  9. Oncology Unbranded

PDF

A global study of multidisciplinary teams and biomarker testing in early-stage NSCLC: Current guideline and literature review

pdf

Perioperative durvalumab for resectable NSCLC (R-NSCLC): Updated outcomes from the phase 3 AEGEAN trial

PPT

Patient-Reported Outcomes (PROs) With Consolidation Durvalumab Versus Placebo Following cCRT in Limited-Stage SCLC: ADRIATIC

PDF

Volrustomig + platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update

PDF

eVOLVE-Meso: A global Phase 3 study of first-line volrustomig plus chemotherapy in unresectable pleural mesothelioma

PDF

Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific, for CPI-naïve Metastatic NSCLC with PD-L1 1-49% or ≥50%

PDF

Trastuzumab deruxtecan monotherapy in pretreated HER2-overexpressing non-small cell lung cancer: DESTINY-Lung03 Part 1D

PDF

Concordance of liquid biopsy and tissue biopsy for the detection of EGFR mutation in stage III NSCLC in the United States

PDF

Osimertinib after CRT in unresectable stage III EGFRm NSCLC: Safety outcomes from the phase 3 LAURA study

PDF

NEOLA: Phase II study of osimertinib treatment before and after chemoradiotherapy in unresectable stage III EGFRm NSCLC

PDF

Real-world outcomes and treatment patterns after first-line osimertinib in patients with advanced NSCLC and uncommon EGFRm

PDF

FLAURA2: Impact of Tumor Burden on Outcomes of 1L Osimertinib ± Chemotherapy in patients with EGFR-mutated Advanced NSCLC

PDF

TRITON: Tremelimumab + durvalumab vs pembrolizumab, + chemotherapy in mNSCLC with STK11, KEAP1 and/or KRAS mutations

PDF

NeoCOAST-2: Efficacy and safety of neoadjuvant durvalumab (D) + novel anticancer agents + CT and adjuvant D ± novel agents in resectable NSCLC

ppt

Datopotamab deruxtecan vs docetaxel in patients with non-small cell lung cancer: Final overall survival from TROPION-Lung01

ppt

Normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung01

PDF

A global study to evaluate access and dynamics of multidisciplinary team care and biomarker testing in early-stage NSCLC

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice